Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MKNK2 | Q9HBH9 | 9/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | IKBKB | O14920 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8241340 | 0.88 | HSD17B10 (0.56) | HSD17B10HPGDALDH1A1MKNK2ATM | |
| SCHEMBL8241663 | 0.81 | HSD17B10 (0.56) | HSD17B10HPGDALDH1A1MKNK2ATM | |
| SCHEMBL8235229 | 0.81 | HSD17B10 (0.56) | HSD17B10HPGDALDH1A1ATMMAPT | |
| SCHEMBL8241753 | 0.81 | HSD17B10 (0.54) | HSD17B10HPGDALDH1A1MKNK2ATM | |
| SCHEMBL8235914 | 0.77 | IKBKB (0.55) | HPGDALDH1A1ATMIKBKBKDM4E | |
| SCHEMBL8243107 | 0.73 | ALDH1A1 (0.53) | HSD17B10HPGDALDH1A1ATMMAPT | |
| SCHEMBL23630827 | 0.70 | HSD17B10 (1.00) | HSD17B10HPGDALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL2185697 | 0.69 | HSD17B10 (0.44) | HSD17B10HPGDALDH1A1MKNK2ATM | |
| SCHEMBL30765149 | 0.69 | HSD17B10 (0.73) | HSD17B10HPGDALDH1A1ATMMAPT | |
| SCHEMBL23112230 | 0.69 | HSD17B10 (0.73) | HSD17B10HPGDALDH1A1ATMMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687501-B2 | Pyridothienopyridazinone derivatives as mGluR1 antagonists | SCHERING CORPORATION (US) | 2010-03-30 | — | — | US | disclosed |
| US-7687501-B2 | Pyridothienopyridazinone derivatives as mGluR1 antagonists | SCHERING CORPORATION (US) | 2010-03-30 | — | — | US | disclosed |
| US-20070072864-A1 | Fused tricyclic mGIuR1 antagonists as therapeutic agents | SCHERING CORPORATION | 2007-03-29 | — | — | US | disclosed |
| US-20070072864-A1 | Fused tricyclic mGIuR1 antagonists as therapeutic agents | SCHERING CORPORATION | 2007-03-29 | — | — | US | disclosed |
| WO-2007032854-A1 | FUSED TRICYCLIC mGluR1 ANTAGONISTS AS THERAPEUTIC AGENTS | SCHERING CORPORATION (US) | 2007-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072864-A1 | Fused tricyclic mGIuR1 antagonists as therapeutic agents | GRM1, GRM3, GRIN1 | HSD17B10 2112/4885HPGD 1841/4885ALDH1A1 1119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.